Drug Type Small molecule drug |
Synonyms DICN, Docetaxel, Liposome-encapsulated docetaxel |
Target |
Mechanism Tubulin inhibitors, Tubulin polymerisation inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC43H53NO14 |
InChIKeyZDZOTLJHXYCWBA-VCVYQWHSSA-N |
CAS Registry114977-28-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Docetaxel liposomal(Sun Pharmaceutical Industries Ltd.) | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | CA | 01 Sep 2014 | |
Prostatic Cancer | Phase 3 | FR | 01 Sep 2014 | |
Prostatic Cancer | Phase 3 | IN | 01 Sep 2014 | |
Prostatic Cancer | Phase 3 | IT | 01 Sep 2014 | |
Prostatic Cancer | Phase 3 | MY | 01 Sep 2014 | |
Prostatic Cancer | Phase 3 | RU | 01 Sep 2014 | |
Breast Cancer | Phase 1 | CN | 17 Oct 2018 | |
Non-Small Cell Lung Cancer | Phase 1 | CN | 17 Oct 2018 |